Skip to contents

Christopher P. Cannon, MD
Senior Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Cardiovascular
75 Francis Street
Boston, MA 02115

Research Location: 900-930 Commonwealth Avenue

Research Email: christopher.cannon@baiminstitute.org

Edit Profile


Research Narrative:

Dr. Cannon is a professor of medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. He earned his MD from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center, and cardiovascular fellowship at Brigham and Women’s Hospital.

Dr. Cannon has published over 1000 original articles, reviews, or electronic publications in the field of acute coronary syndromes and prevention and has authored or edited 18 books. He has received numerous awards, including leadership awards from the American College of Cardiology and the American Heart Association.

He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, and IMPROVE IT trials.  Dr. Cannon serves as Executive Director of Cardiometabolic Trials at the Baim Institute for Clinical Research.  He lead the RE-DUAL PCI trial, studying novel anticoagulant strategies in patients with atrial fibrillation undergoing stenting, and collaborates on many other trials and registry projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids and prevention.  


Education:
Columbia University, College of Physicians and Surgeons, 1986, MD
Yale College, 1982, BA

Other Professional Activities:
Executive Director Cardiometabolic Trials, Harvard Clinical Research Institute

Publications (Pulled from Harvard Catalyst Profiles):

1. Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, Califf RM, Braunwald E, Blazing MA. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019 Jul 17.

2. Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 Jul 12; 288:85-93.

3. Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial. Circulation. 2019 Jul 11.

4. Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, Vranckx P, Lopes RD, Montalescot G, Cannon CP, Ten Berg J, Gersh BJ, Bhatt DL, Angiolillo DJ. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jul 09; 74(1):83-99.

5. Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, Alexanian C, Januzzi JL. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®. ESC Heart Fail. 2019 Aug; 6(4):784-792.

6. Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, Alexanian C, Januzzi JL. Alteration of medical therapy in patients with heart failure relative to change in symptom severity. ESC Heart Fail. 2019 Jul 03.

7. Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger CB, Verheugt FWA, Li J, Ten Berg JM, Sarafoff N, Gibson CM, Alexander JH. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. JAMA Cardiol. 2019 Jun 19.

8. Cannon CP, Khan I, Klimchak AC, Sanchez RJ, Sasiela WJ, Massaro JM, D'Agostino RB, Reynolds MR. Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. Am Heart J. 2019 Jun 12; 216:30-41.

9. Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 Jun 08.

10. Arnold SV, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Mues KE, Alam S, Elliott-Davey M, Bhatt DL, Cannon CP, Kosiborod M. Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation. 2019 Aug 13; 140(7):618-620.